The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.
View All Commentary (ELN)
Recs
stockdoc00 (95.13) Submitted: 9/14/08 9:51 PM : Start Price: $11.12 ELN Score: -2.88
A high risk high reward company with a very promising pipeline, in particular for Alzheimer's and multiple sclerosis. The recent Tysabri scare that precipitated its sudden drop was a huge overreaction by the investor community. While its fundamentals are not up to par compared with other premier pharma co's, it is way oversold and a great buy at its current levels.
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK